This Scientist II will independently design, execute, and analyze research studies and will drive one or more analytical development projects for AAV-based gene therapy programs. The role provides technical leadership in the development, optimization, qualification, validation, and transfer of analytical assays, including cell-based potency and molecular methods such as qPCR and ddPCR. The Scientist II will apply broad scientific knowledge and novel approaches to establish AAV mechanisms of action in cellular systems, resolve moderately complex technical issues, and support GMP manufacturing, material release, and regulatory submissions in collaboration with groups across CMC, Quality, QC, and external partners.
The ideal candidate is highly collaborative, detail-oriented, able to manage multiple priorities, and effective in a fast-paced environment. The Scientist II is expected to exercise sound scientific judgment, communicate complex technical issues clearly, build alignment across functions, and serve as a technical resource to colleagues. This is a highly visible and impactful role in our CMC organization.
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.
